Nanomedicine in Cardiovascular Diseases: Diagnostic and Therapeutic Innovations for Better Health

Simple item page
dc.contributor.authorMadhukar P.
dc.contributor.authorSingh V.K.
dc.contributor.authorChauhan S.B.
dc.contributor.authorTiwari R.
dc.contributor.authorKumar A.
dc.contributor.authorRajneesh
dc.contributor.authorKumar R.
dc.date.accessioned2025-01-13T07:07:04Z
dc.date.available2025-01-13T07:07:04Z
dc.date.issued2024
dc.description.abstractCardiovascular diseases (CVDs) are a major cause of global mortality, responsible for approximately 17.9 million deaths in 2019 and 20.5 million deaths in 2021. Limited access to specialised testing, especially for marginalised population, complicate the diagnosis of cardiovascular conditions. Disparities in treatment, sub-optimal pharmaceuticals, toxicity from conventional drugs, diagnostic errors, and the underutilization of non-invasive diagnostic methods contribute to adverse outcomes. Additionally, cost and insurance barriers hinder access to necessary tests, delaying diagnosis and treatment. Therefore, there is an urgent need for improved therapies for CVDs. Additionally, cost and insurance barriers hinder access to necessary tests, delaying diagnosis and treatment. Therefore, there is an urgent need for improved therapies for CVDs. Nanotechnology, which involves the precise control and manipulation of materials at the atomic and molecular levels, shows promise in addressing cardiovascular diseases. Nanoparticles, with their unique properties such as ultra-small size, tunable physicochemical characteristics, and biocompatibility, offer potential for targeted drug delivery. Nanoparticle-based drug delivery systems can enhance therapeutic effectiveness, prolong drug action, improve drug absorption, target specific areas passively or actively, reduce drug resistance, and minimize adverse drug reactions. This chapter comprehensively examines the use of nanoparticle-based diagnostic methods, targeting strategies, and therapeutic interventions for cardiovascular diseases, providing a thorough explanation of the fundamental principles and key considerations in this field. � The Author(s), under exclusive license to Springer Nature Switzerland AG 2024.
dc.identifier.doi10.1007/978-3-031-72467-1_9
dc.identifier.issn25238027
dc.identifier.urihttps://dl.bhu.ac.in/ir/handle/123456789/2614
dc.language.isoen
dc.publisherSpringer Science and Business Media B.V.
dc.subjectAtherosclerosis
dc.subjectCardiovascular diseases (CVDs)
dc.subjectNanoparticles
dc.subjectNanotechnology
dc.titleNanomedicine in Cardiovascular Diseases: Diagnostic and Therapeutic Innovations for Better Health
dc.typeBook chapter
journal.titleNanotechnology in the Life Sciences
journalvolume.identifier.volumePart F3808

Files

Collections

2024